INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy
Rhea-AI Summary
INVO Fertility (Nasdaq: IVF) announced an executive realignment effective Dec. 30, 2025 to support its clinic-acquisition growth strategy. Terah Krigsvold, controller since Dec. 2020, is appointed chief financial officer, replacing Andrea Goren. Andrea Goren, CFO since July 2021, becomes chief business officer and CEO of INVO Centers LLC, the company's wholly owned clinic subsidiary, to lead acquisitions and new clinic launches. Management says the move preserves finance continuity while shifting Andrea to focus on growth and transactions. The release notes Andrea has worked on approximately $1 billion of financing and acquisition deals in his career.
Positive
- Internal CFO promotion preserves accounting continuity
- Chief business officer role dedicated to acquisitions and clinic launches
- Terah Krigsvold has company finance experience since Dec. 2020
- Andrea Goren led ~$1 billion financing and acquisition transactions in his career
- Realignment positioned to support stated path to profitability
Negative
- Leadership transition may introduce short-term execution risk
- Growth strategy remains dependent on successful acquisitions and clinic launches
News Market Reaction
On the day this news was published, IVF gained 9.99%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.4% during that session. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $178K to the company's valuation, bringing the market cap to $2M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While IVF was down 11.53%, key peers like VERO (-1.19%), TIVC (-1.99%), NAOV (-1.95%), and NUWE (-9.9%) also traded lower, but no coordinated sector momentum signal was detected.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Clinic acquisition deal | Positive | -9.8% | Signed definitive agreement to acquire Family Beginnings fertility clinic. |
| Dec 02 | Private placement | Negative | -11.8% | Announced $4.0M at-the-market private placement with warrants. |
| Nov 28 | Acquisition intent | Positive | +11.0% | Announced intent to acquire Family Beginnings fertility clinic in Indiana. |
| Nov 25 | Reverse stock split | Negative | -20.2% | Declared 1-for-8 reverse split effective Nov 28, 2025. |
| Nov 17 | Earnings update | Negative | -5.1% | Reported Q3 2025 revenue growth but higher net loss and negative EBITDA. |
Recent history shows frequent negative reactions to capital structure and financing events, with acquisitions sometimes rewarded but definitive deal terms drawing selling pressure.
Over the past few months, INVO Fertility has combined strategic clinic expansion with significant balance-sheet activity. On Nov 17, 2025, Q3 results showed revenue of $1.757M but wider losses. A 1-for-8 reverse split on Nov 28, 2025 and a $4.0M private placement on Dec 2, 2025 both saw negative price reactions. Announcements to acquire and then sign a definitive agreement for the Family Beginnings clinic in late November and on Dec 17, 2025 fit the clinic roll-up strategy. Today’s leadership realignment centers management on executing that growth plan through INVO Centers LLC.
Market Pulse Summary
The stock moved +10.0% in the session following this news. A strong positive reaction aligns with management’s intent to sharpen execution on the clinic acquisition and growth strategy by elevating an experienced controller to CFO and shifting a deal-focused executive to lead INVO Centers LLC. Past financing and structural actions, such as the $4.0M private placement and 1-for-8 reverse split, drew selling pressure, so sustained gains would depend on confidence that this reorganization improves profitability and integration of deals like the Family Beginnings acquisition.
AI-generated analysis. Not financial advice.
Terah Krigsvold to replace Andrea Goren as CFO, who is named chief business officer and CEO of INVO Centers LLC to focus on growth efforts
SARASOTA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced changes to its executive leadership team to align its human resources with the Company’s growth strategy focused on the acquisition and establishment of fertility clinics and ancillary organizations.
Terah Krigsvold, who has served as INVO’s controller since December 2020, has been appointed as the Company’s new chief financial officer, replacing Andrea Goren. Mr. Goren, who has served as INVO chief financial officer since July 2021, has been appointed as chief business officer, as well as chief executive officer of INVO Centers LLC, the Company’s wholly owned subsidiary focused on fertility clinics.
“As we continue to grow our presence in the fertility sector and based on Terah and Andrea’s commitment, hard work and growth over the past five years, this realignment of roles strengthens our ability to execute our plan to grow the business and reach profitability,” said Steve Shum, CEO of INVO. “I have worked with Terah for the past seven years and am thrilled at the progress she has demonstrated over that time. This promotion is very well deserved and ensures continuity, as well as keeping our finance and accounting functions in a strong pair of hands. With this change, Andrea is now able to focus more of his time on leading the execution of our primary growth strategy, acquisitions, and, in due course, new clinic launches. Andrea has worked on approximately
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
Who is the new CFO of INVO Fertility (IVF) and when was the appointment?
What new role does Andrea Goren hold at INVO Fertility (IVF)?
How does the management change affect INVO Fertility’s growth strategy (IVF)?
What experience does Andrea Goren bring to INVO Fertility (IVF) for acquisitions?
Will the CFO change at INVO Fertility (IVF) affect financial continuity?
What is INVO Centers LLC’s role after the leadership realignment at INVO Fertility (IVF)?
